FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2110266543> ?p ?o ?g. }

• W2110266543 endingPage "92" @default.
• W2110266543 startingPage "985" @default.
• W2110266543 abstract "Melanoma tumors and cultured cell lines are relatively resistant to the cytotoxic effects of ionizing radiation, thereby limiting the use of radiotherapy for the clinical treatment of melanoma. New strategies for sensitizing melanoma cells therefore deserve examination. In an attempt to identify and target signaling pathways that contribute to radioresistance, we investigated the role of nuclear factor-kappaB (NF-kappaB), a transcription factor known to inhibit apoptosis induced by a variety of stimuli and promote radioresistance. Two human metastatic melanoma cell lines, A375 and MeWo, were used to examine the radiosensitizing effects of inhibitors of the NF-kappaB pathway. Nuclear extracts from these cell lines were tested for active NF-kappaB using the electrophoretic mobility shift assay. Both melanoma cell lines had constitutively activated NF-kappaB as observed by electrophoretic mobility shift assay. In an attempt to reverse NF-kappaB activity, cells were treated either with vehicle alone (DMSO) or with a proteasome inhibitor Z-Leu-Leu-Leu-H (MG132; 10 micromol/L for 2 hours prior to irradiation) that inhibited both constitutive and radiation-induced NF-kappaB activity. The clonogenic cell survival assay showed that pretreatment with MG132 enhanced tumor cell radiosensitivity with the survival factor at 2 Gy being reduced from 48 +/- 0.8% and 48 +/- 1.6% in vehicle-treated cells to 27.7 +/- 0.32% and 34.3 +/- 0.7% in MG132-treated MeWo and A375 cells, respectively. To test the role of NF-kappaB in radioresistance more directly, MeWo cells were stably transfected with a dominant-negative mutant IkappaBalpha construct, which led to the inhibition of both constitutive and radiation-induced NF-kappaB activity. A modest restoration of radiosensitivity was also observed in the stably transfected MeWo cells with survival factor at 2 Gy values being reduced from 47 +/- 0.8% in parental MeWo cells to 32.9 +/- 0.7% in stable transfectants. Because constitutively activated mitogen-activated protein kinase kinase (MEK) pathway has been shown to lead to activated NF-kappaB, we wanted to determine the relative contribution of activated MEK in the human melanoma cells. To test this, MeWo and A375 melanoma cells were exposed to the MEK inhibitor PD184352. Treatment with PD184352 partially reversed NF-kappaB activity but did not impart radiation sensitivity to these cells. Our results indicate that activated NF-kappaB may be one of the pathways responsible for the radioresistance of melanoma cells and that strategies for inhibiting its influence may be useful in restoring the radioresponse of melanomas." @default.
• W2110266543 created "2016-06-24" @default.
• W2110266543 creator A5004888325 @default.
• W2110266543 creator A5012720004 @default.
• W2110266543 creator A5048077180 @default.
• W2110266543 creator A5066219206 @default.
• W2110266543 creator A5068301962 @default.
• W2110266543 creator A5085523826 @default.
• W2110266543 date "2004-08-01" @default.
• W2110266543 modified "2023-09-23" @default.
• W2110266543 title "Inhibition of constitutively activated nuclear factor-kappaB radiosensitizes human melanoma cells." @default.
• W2110266543 cites W1483628400 @default.
• W2110266543 cites W1492381941 @default.
• W2110266543 cites W1492606093 @default.
• W2110266543 cites W1928813052 @default.
• W2110266543 cites W1970534746 @default.
• W2110266543 cites W1978701756 @default.
• W2110266543 cites W1979634801 @default.
• W2110266543 cites W1988579238 @default.
• W2110266543 cites W2019655159 @default.
• W2110266543 cites W2020946962 @default.
• W2110266543 cites W2022683869 @default.
• W2110266543 cites W2026158949 @default.
• W2110266543 cites W2032531389 @default.
• W2110266543 cites W2038470330 @default.
• W2110266543 cites W2040470926 @default.
• W2110266543 cites W2056831005 @default.
• W2110266543 cites W2063189553 @default.
• W2110266543 cites W2080070482 @default.
• W2110266543 cites W2080103573 @default.
• W2110266543 cites W2081848947 @default.
• W2110266543 cites W2086177031 @default.
• W2110266543 cites W2090379314 @default.
• W2110266543 cites W2102714295 @default.
• W2110266543 cites W2104324075 @default.
• W2110266543 cites W2111077139 @default.
• W2110266543 cites W2114001916 @default.
• W2110266543 cites W2119822961 @default.
• W2110266543 cites W2129849803 @default.
• W2110266543 cites W2135473096 @default.
• W2110266543 cites W2137651777 @default.
• W2110266543 cites W2138077682 @default.
• W2110266543 cites W2142093446 @default.
• W2110266543 cites W2170506785 @default.
• W2110266543 cites W2315879546 @default.
• W2110266543 cites W2324000374 @default.
• W2110266543 cites W2324787672 @default.
• W2110266543 cites W2332687699 @default.
• W2110266543 cites W2414559303 @default.
• W2110266543 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15299081" @default.
• W2110266543 hasPublicationYear "2004" @default.
• W2110266543 type Work @default.
• W2110266543 sameAs 2110266543 @default.
• W2110266543 citedByCount "18" @default.
• W2110266543 countsByYear W21102665432012 @default.
• W2110266543 countsByYear W21102665432013 @default.
• W2110266543 countsByYear W21102665432014 @default.
• W2110266543 countsByYear W21102665432015 @default.
• W2110266543 countsByYear W21102665432016 @default.
• W2110266543 countsByYear W21102665432017 @default.
• W2110266543 countsByYear W21102665432018 @default.
• W2110266543 countsByYear W21102665432020 @default.
• W2110266543 countsByYear W21102665432021 @default.
• W2110266543 crossrefType "journal-article" @default.
• W2110266543 hasAuthorship W2110266543A5004888325 @default.
• W2110266543 hasAuthorship W2110266543A5012720004 @default.
• W2110266543 hasAuthorship W2110266543A5048077180 @default.
• W2110266543 hasAuthorship W2110266543A5066219206 @default.
• W2110266543 hasAuthorship W2110266543A5068301962 @default.
• W2110266543 hasAuthorship W2110266543A5085523826 @default.
• W2110266543 hasConcept C104317684 @default.
• W2110266543 hasConcept C117262875 @default.
• W2110266543 hasConcept C126322002 @default.
• W2110266543 hasConcept C153911025 @default.
• W2110266543 hasConcept C183978625 @default.
• W2110266543 hasConcept C185592680 @default.
• W2110266543 hasConcept C190283241 @default.
• W2110266543 hasConcept C206684579 @default.
• W2110266543 hasConcept C2776428644 @default.
• W2110266543 hasConcept C2777658100 @default.
• W2110266543 hasConcept C2778367456 @default.
• W2110266543 hasConcept C2778506107 @default.
• W2110266543 hasConcept C502942594 @default.
• W2110266543 hasConcept C509974204 @default.
• W2110266543 hasConcept C54355233 @default.
• W2110266543 hasConcept C55493867 @default.
• W2110266543 hasConcept C58962609 @default.
• W2110266543 hasConcept C71924100 @default.
• W2110266543 hasConcept C81885089 @default.
• W2110266543 hasConcept C86339819 @default.
• W2110266543 hasConcept C86803240 @default.
• W2110266543 hasConceptScore W2110266543C104317684 @default.
• W2110266543 hasConceptScore W2110266543C117262875 @default.
• W2110266543 hasConceptScore W2110266543C126322002 @default.
• W2110266543 hasConceptScore W2110266543C153911025 @default.
• W2110266543 hasConceptScore W2110266543C183978625 @default.
• W2110266543 hasConceptScore W2110266543C185592680 @default.
• W2110266543 hasConceptScore W2110266543C190283241 @default.

• next